Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Geoffrey W. Chan"'
Autor:
Dagmar Pospisilova, Christine K Bailey, Thirachit Chotsampancharoen, James B. Bussel, Patcharee Komvilaisak, Susanne Holzhauer, Lisa M Marcello, Elena K. Donyush, John D. Grainger, Ugo Ramenghi, Franco Locatelli, Geoffrey W. Chan, Karen Chagin, Richard S. Lemons, Nongnuch Sirachainan, Guillermo Drelichman, Darintr Sosothikul, Vladimir Lebedev, Malini Iyengar, Bunchoo Pongtanakul, Kalpana Bakshi, Dickens Theodore
Publikováno v:
The Lancet. 386:1649-1658
Summary Background The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia. We aimed to investigate the safety and efficacy of eltrombopag for children with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f56e2aa9aa8b0f253582612cc827b55
https://doi.org/10.1016/s0140-6736(15)61107-2
https://doi.org/10.1016/s0140-6736(15)61107-2
Autor:
Geoffrey W. Chan, Kevin H. Laubscher, Donna Sedoti, Eric Lewis, William N. Patton, Yan Yan Zhou, Philip Witman, Lei Fang, Thomas J. Kipps, Andrew C Butler, Robert Lindeman, Roxanne C. Jewell
Publikováno v:
Leukemia & lymphoma, vol 56, iss 10
This open-label, phase 1 study evaluated the effects of ofatumumab on QTc intervals, safety, efficacy, B-cell and neutrophil counts, complement levels, and cytokine and chemokine concentrations. Fourteen patients with fludarabine-refractory chronic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caa508b7cc9ce85b0e413809db57007f
https://doi.org/10.3109/10428194.2015.1014357
https://doi.org/10.3109/10428194.2015.1014357
Publikováno v:
Bone Marrow Transplantation. 46:300-307
BSI and acute GVHD (aGVHD) are serious complications of HSCT. We hypothesized that the two events were not independent of one another. We studied (1) associations between BSI and aGVHD; (2) the impact of BSI and/or aGVHD on death within 100 days afte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::348924fc4d39c4cf323ac98f4b87b396
https://doi.org/10.1038/bmt.2010.112
https://doi.org/10.1038/bmt.2010.112
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Autor:
Tomas Kozak, Geoffrey W. Chan, Randy Davis, Peter Hillmen, Cathy D. Williams, Charlotte A. Russell, Richard R. Furman, Marek Trneny, Nedjad Losic, Anders Österborg, Tadeusz Robak, Magdalena Piotrowska, Thomas J. Kipps, Stephan Stilgenbauer, Joris Wilms, William G. Wierda, Jiří Mayer, Swami Padmanabhan, Andrzej Hellmann, Martin J. S. Dyer
Publikováno v:
Journal of Clinical Oncology. 28:1749-1755
Purpose New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::705d3202cbac46d2800f50e9aec71497
https://doi.org/10.1200/jco.2009.25.3187
https://doi.org/10.1200/jco.2009.25.3187
Autor:
Je-Hwan Lee, Yoo-Jin Kim, Tzeon Jye Chiou, John Feigert, John M. Bennett, Marco Ruggeri, Amit Verma, Gorin Nc, Uwe Platzbecker, Geoffrey W. Chan, Souria Dougherty, Nicole L. Stone, Gregory Cheng, Camille N. Abboud, Raymond S.M. Wong, Suman Kambhampati, Jun Ho Jang, Frank L. Mannino, Aristoteles Giagounidis, Chien Yuan Chen, Roger M. Lyons, Sergio Araujo, Peter L. Greenberg, Shih-Peng Yeh, Yasser Mostafa Kamel, Katharina Götze, Valeria Santini, Brendan M. Johnson
Publikováno v:
The Lancet. Haematology. 2(10)
Summary Background Patients with myelodysplastic syndrome or acute myeloid leukaemia who are thrombocytopenic and unable to receive disease-modifying therapy have few treatment options. Platelet transfusions provide transient benefit and are limited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2043d33c8504613e36e7498d03e0294
https://pubmed.ncbi.nlm.nih.gov/26686035
https://pubmed.ncbi.nlm.nih.gov/26686035
Autor:
Geoffrey W. Chan, Yasser Mostafa Kamel, Frederic Forget, Paul Burgess, Eric S. Winer, Boguslawa Karaszewska, Sebastian Bauer, Brendan M. Johnson, Dilawar Khan, Howard Safran, Denise C. Althouse
9602 Background: A phase 1 EPAG study showed favorable results for the treatment of CTx-induced TCP in pts receiving GEM-based CTx. Methods: This was a phase 2, blinded, PBO-controlled, multicenter study in adults with solid tumors and TCP receiving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6c98e3f525225169e07bacd9a8d7d3
http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.9602
http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.9602
Autor:
Francine M. Foss, Gina DiVenuti, H Grodman, Kevin M. Chin, Kenneth B. Miller, Geoffrey W. Chan, Andreas K. Klein, K Stiffler, Kellie Sprague
Publikováno v:
Bone Marrow Transplantation. 35:1187-1193
We enrolled 25 patients with extensive, steroid-refractory chronic graft-versus-host disease (cGVHD) in a prospective trial evaluating the efficacy of extracorporeal photophoresis (ECP) in both skin and visceral cGVHD. The median time from transplant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2a85c63e51e222cbd45dc69d4df7d7d
https://doi.org/10.1038/sj.bmt.1704984
https://doi.org/10.1038/sj.bmt.1704984
Publikováno v:
Biology of Blood and Marrow Transplantation. 9:170-176
Graft-versus-host disease (GVHD) causes significant morbidity and mortality in patients undergoing allogeneic bone marrow transplantation following either a conventional or reduced-intensity preparative regimen. In a murine model, inactivation of hos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79a55944107aea0c99f8a5db9d3ac2b8
https://doi.org/10.1053/bbmt.2003.50006
https://doi.org/10.1053/bbmt.2003.50006
Autor:
Eric Lewis, Donna Sedoti, Oliver Wright, Geoffrey W. Chan, Jodi L Carey, Charles S Hottenstein, Lei Fang, Kevin H. Laubscher, Astrid McKeown, Iestyn Dixon, Sarah West, Zarina Gafoor, Roxanne C. Jewell
Publikováno v:
Journal of clinical pharmacology. 55(1)
Ofatumumab is a human monoclonal antibody that binds to a unique CD20 epitope on the surface of B lymphocytes, resulting in efficient lysis of CD20-expressing cells via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::973484afce14cec17840a9dcb620ef34
https://pubmed.ncbi.nlm.nih.gov/25103870
https://pubmed.ncbi.nlm.nih.gov/25103870
Autor:
Swaminathan Padmanabhan, Anders Österborg, Geoffrey W. Chan, Steen Lisby, Ira Gupta, William G. Wierda
Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab (FA-ref) and patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::908aedf815f30813c6b97c539d835d32
https://europepmc.org/articles/PMC4916553/
https://europepmc.org/articles/PMC4916553/